Log in

Interpace Diagnostics Group Stock Price, News & Analysis (NASDAQ:IDXG)

$0.82
-0.01 (-1.21 %)
(As of 10/14/2019 06:00 AM ET)
Today's Range
$0.81
Now: $0.82
$0.84
50-Day Range
$0.71
MA: $0.77
$0.84
52-Week Range
$0.67
Now: $0.82
$1.55
Volume88,362 shs
Average Volume181,226 shs
Market Capitalization$31.15 million
P/E RatioN/A
Dividend YieldN/A
Beta2.29
Interpace Diagnostics Group, Inc develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using its proprietary PathFinder platform; ThyGenX, an oncogenic mutation panel that helps identify malignant thyroid nodules; and ThyraMIR, an microRNA gene expression assay that helps to classify risk of cancer in thyroid nodules. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Services
SectorMedical
Current SymbolNASDAQ:IDXG
CUSIP69329V10
Phone855-776-6419

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$21.90 million
Book Value$1.15 per share

Profitability

Net Income$-12,190,000.00

Miscellaneous

Employees89
Market Cap$31.15 million
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable

Receive IDXG News and Ratings via Email

Sign-up to receive the latest news and ratings for IDXG and its competitors with MarketBeat's FREE daily newsletter.


Interpace Diagnostics Group (NASDAQ:IDXG) Frequently Asked Questions

What is Interpace Diagnostics Group's stock symbol?

Interpace Diagnostics Group trades on the NASDAQ under the ticker symbol "IDXG."

How were Interpace Diagnostics Group's earnings last quarter?

Interpace Diagnostics Group Inc (NASDAQ:IDXG) posted its earnings results on Tuesday, August, 13th. The business services provider reported ($0.11) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.06) by $0.05. The business services provider had revenue of $6.27 million for the quarter, compared to the consensus estimate of $6.70 million. Interpace Diagnostics Group had a negative net margin of 65.86% and a negative return on equity of 42.91%. View Interpace Diagnostics Group's Earnings History.

When is Interpace Diagnostics Group's next earnings date?

Interpace Diagnostics Group is scheduled to release their next quarterly earnings announcement on Tuesday, November 12th 2019. View Earnings Estimates for Interpace Diagnostics Group.

What guidance has Interpace Diagnostics Group issued on next quarter's earnings?

Interpace Diagnostics Group updated its FY 2019 earnings guidance on Tuesday, August, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $33-36 million, compared to the consensus revenue estimate of $33.04 million.

What price target have analysts set for IDXG?

4 brokers have issued twelve-month price targets for Interpace Diagnostics Group's shares. Their predictions range from $2.00 to $4.00. On average, they expect Interpace Diagnostics Group's share price to reach $3.25 in the next year. This suggests a possible upside of 298.5% from the stock's current price. View Analyst Price Targets for Interpace Diagnostics Group.

What is the consensus analysts' recommendation for Interpace Diagnostics Group?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Interpace Diagnostics Group in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Interpace Diagnostics Group.

What are Wall Street analysts saying about Interpace Diagnostics Group stock?

Here are some recent quotes from research analysts about Interpace Diagnostics Group stock:
  • 1. Maxim Group analysts commented, "Interpace Diagnostics reported 4Q18 and FY18 net revenue of $5.8M, up 33% y/y, and $21.9M, up 38% y/y, respectively, due to expansion in units and improved reimbursement. Net loss was ($4.0M) for the quarter and ($12.2M) for the year. The company ended the period with $6.1M in cash, not including $6.1M in net proceeds from a January 2019 equity financing. Interpace also has a $4M credit facility in place." (3/20/2019)
  • 2. HC Wainwright analysts commented, "Our 12-month price target is derived from an estimated market value of the firm at $120M. This includes a discounted cash flow analysis based asset value for the company’s three commercialized laboratory-developed tests (LDTs), with a 15% discount rate and a 2% terminal growth rate, and assuming 39M shares outstanding at the end of 2019." (2/20/2019)
  • 3. According to Zacks Investment Research, "Interpace Diagnostics Group, Inc. provides molecular diagnostic tests. The company's test consists of ThyGenX Thyroid Oncogene Panel (R), Thyroid miRNA(TM) and PancraGen(TM). Interpace Diagnostics Group Inc, formerly known as PDI Inc., is headquartered in Parsippany, New Jersey. " (1/9/2019)

Has Interpace Diagnostics Group been receiving favorable news coverage?

Press coverage about IDXG stock has been trending negative this week, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Interpace Diagnostics Group earned a news sentiment score of -2.6 on InfoTrie's scale. They also assigned news articles about the business services provider a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Interpace Diagnostics Group.

Who are some of Interpace Diagnostics Group's key competitors?

What other stocks do shareholders of Interpace Diagnostics Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Interpace Diagnostics Group investors own include Histogenics (HSGX), Magnegas Applied Tchnlgy Sltns (MNGA), Genocea Biosciences (GNCA), Synergy Pharmaceuticals (SGYP), Advanced Micro Devices (AMD), Novavax (NVAX), SCYNEXIS (SCYX), Trevena (TRVN), AVEO Pharmaceuticals (AVEO) and Square (SQ).

Who are Interpace Diagnostics Group's key executives?

Interpace Diagnostics Group's management team includes the folowing people:
  • Mr. Jack E. Stover, CEO, Pres & Director (Age 66)
  • Mr. James E. Early, CFO, Sec. & Treasurer (Age 65)
  • Mr. Gregory Richard, Sr. VP & Chief Commercial Officer (Age 52)
  • Mr. Glenn Gershon, Sr. VP of Operations
  • Mr. Thomas John Freeburg, Chief Accounting Officer (Age 51)

How do I buy shares of Interpace Diagnostics Group?

Shares of IDXG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Interpace Diagnostics Group's stock price today?

One share of IDXG stock can currently be purchased for approximately $0.82.

How big of a company is Interpace Diagnostics Group?

Interpace Diagnostics Group has a market capitalization of $31.15 million and generates $21.90 million in revenue each year. The business services provider earns $-12,190,000.00 in net income (profit) each year or ($0.43) on an earnings per share basis. Interpace Diagnostics Group employs 89 workers across the globe.View Additional Information About Interpace Diagnostics Group.

What is Interpace Diagnostics Group's official website?

The official website for Interpace Diagnostics Group is http://www.interpacediagnostics.com/.

How can I contact Interpace Diagnostics Group?

Interpace Diagnostics Group's mailing address is MORRIS CORPORATE CENTER 1 BUILDING C 300 INTERPACE PARKWAY, PARSIPPANY NJ, 07054. The business services provider can be reached via phone at 855-776-6419 or via email at [email protected]


MarketBeat Community Rating for Interpace Diagnostics Group (NASDAQ IDXG)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  243 (Vote Outperform)
Underperform Votes:  178 (Vote Underperform)
Total Votes:  421
MarketBeat's community ratings are surveys of what our community members think about Interpace Diagnostics Group and other stocks. Vote "Outperform" if you believe IDXG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IDXG will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/14/2019 by MarketBeat.com Staff

Featured Article: Bid-Ask Spread

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel